RGA Q1 2026 Earnings Transcript

Reinsurance Group of America reported Q1 pretax adjusted operating income of $611 million, or $6.97 per share, with 16.2% adjusted operating ROE and $50 million of share repurchases. Premium growth was solid at 5% overall, excess capital stood at $2.4 billion, and management reiterated a 20%-30% long-term capital return target plus $400 million of planned debt reduction in 2026. The call also highlighted favorable economic claims experience of $117 million in the quarter and $343 million cumulative since 2023, though most of that benefit will be recognized gradually over time.

Analysis

RGA is one of the cleaner beneficiaries of a late-cycle reinsurance market because its earnings lever is no longer just spread income; it is increasingly mix-shift plus capital velocity. The quarter suggests the company is effectively monetizing a structural scarcity premium in biometric-heavy transactions while avoiding the commoditized, balance-sheet-only deals where pricing has tightened. That should keep ROE resilient even if top-line premium growth moderates, because the real driver is the spread between underwriting discipline and cost of capital, not raw volume.

The underappreciated second-order effect is that management is signaling a higher-quality capital return regime at the same time it is still finding attractive deployment. That combination is usually supportive for valuation because it reduces the market’s fear that capital is trapped inside the float; here, excess capital and deployable capital both appear ample enough to sustain buybacks while still funding growth and debt reduction. If the market starts to believe the $20mm annual runoff from favorable claims is durable, consensus EPS could drift up over the next several quarters without requiring any multiple expansion.

The main risk is not near-term underwriting; it is reinsurance competition migrating from vanilla asset-intensive deals into adjacent biometric structures once incumbents realize where the economics are strongest. That is a months-to-years issue, but it could pressure renewal terms and pipeline quality if large global players decide to subsidize market share. Regulatory changes look more like friction than thesis-breakers; the bigger catalyst to monitor is whether capital return accelerates enough to force the market to re-rate RGA as a compounder rather than a cyclical reinsurer.

Key Decisions for Investors

• Long RGA versus short EQH on a 3-6 month horizon: RGA has cleaner capital deployment optionality and less dependence on volatile asset-intensive spread trades; EQH’s upside is more tied to market-sensitive flows. Risk: if capital markets rally sharply and variable income surprises to the upside, the pair can compress.
• Buy RGA common on weakness below the post-earnings move if the stock remains below 14-15x forward earnings; target a 6-9 month hold for buyback + deployment-driven multiple support. Risk/reward skews positive if management continues to return 20%-30% of earnings.
• Sell out-of-the-money puts in RGA 3-6 months out, especially on pullbacks tied to noise around regulatory headlines. This monetizes high implied volatility around a business with visible capital support; risk is a sharp unwind if competitive pressure emerges faster than expected.
• Consider a relative long RGA / short broader life insurers basket (e.g., WFC/insurance-sensitive financials via sector proxies) for 6-12 months. Thesis: RGA’s biometric moat and capital return should outperform peers with more commodity-like spread exposure.
• If you want convexity, structure a call spread in RGA rather than outright stock for the next earnings cycle; the catalyst path is gradual, not binary. Best case is multiple expansion as the market prices in sustained EPS grind and capital returns.